Gallium-67 Citrate Imaging: Physics and QC

Gallium-67 citrate is a four-photopeak, electron-capture SPECT agent whose imaging physics still teaches the fundamentals of multi-energy nuclear medicine: it demands a medium-energy collimator, a triple energy-window acquisition, and delayed 48-to-72-hour imaging, and it carries a relatively high patient dose. Understanding how Ga-67 is imaged — and why — sharpens the physics behind collimator choice, energy-window design, and dosimetry that carry over to every gamma camera study.¹²

Gallium-67 once anchored lymphoma staging and infection localization. Today FDG PET/CT has taken most of those indications, but Ga-67 has not vanished: it retains a defined niche, most durably in spine infection, and it remains one of the clearest teaching cases in nuclear medicine for how photon energy drives every acquisition decision.²³⁴ This guide covers Ga-67's decay data, why it needs a medium-energy collimator and a three-window acquisition, its dosimetry, practical protocol and QC design, and where it still fits. DRPS supports these programs through its PET/CT and nuclear medicine physics and medical physics consulting services.

Introduction

Every imaging radionuclide is a compromise between the physics of its emissions and the biology of its uptake. Technetium-99m is the workhorse precisely because its single 140 keV photon is nearly ideal for a sodium-iodide gamma camera. Gallium-67 sits at the opposite extreme: it emits four significant photons spanning 93 to 393 keV, decays over days rather than hours, and localizes slowly. Each of those properties forces a specific engineering response — a heavier collimator, a multi-window acquisition, a delayed imaging schedule — and that is exactly what makes it instructive.¹

The clinical story of gallium is one of gradual replacement. It was, for decades, the agent for lymphoma restaging and for chasing occult infection and fever of unknown origin. As FDG PET/CT matured, gallium's lower resolution, multi-day protocol, and higher dose made it the second choice for most of those tasks.²³ But "second choice" is not "no choice": in facilities without PET access, and in specific problems like spondylodiscitis, Ga-67 SPECT/CT still earns its place.⁴⁵

This post treats Ga-67 as both a working clinical tool and a physics lesson, because getting a gallium study right requires understanding the emissions in a way that a single-photopeak Tc-99m study never demands.

Topic Explanation

The decay scheme

Gallium-67 decays by electron capture (100%) to stable zinc-67, with a physical half-life of 3.26 days (about 78.3 hours). Because it decays by electron capture rather than beta emission, its useful output is a set of gamma rays and characteristic X-rays — no particulate therapy component, purely a diagnostic photon emitter.¹

The four imaging photopeaks, with their emission probabilities per decay, are:

The practical acquisition uses a triple energy window centered on the 93, 185, and 300 keV peaks. The 393 keV line, although present, is typically left out: its yield is low and its high energy aggravates septal penetration for little diagnostic gain. Summing three windows instead of one recovers count sensitivity that would otherwise be lost by imaging a low-yield, multi-line emitter.¹⁶

Why gallium is a "hard" imaging problem

Three features make Ga-67 harder to image well than Tc-99m:

• High photon energies. The 300 and 393 keV photons penetrate the thin septa of a standard low-energy collimator, so a heavier collimator is mandatory (below).
• Low per-decay yield spread over four lines. No single photopeak carries the majority of the signal, so multi-window acquisition and adequate imaging time are needed for counts.
• Slow, distributed biodistribution. Gallium binds to transferrin and localizes in inflammatory and some tumor tissues over days, with slow blood-pool and bowel clearance — which sets both the imaging delay and the critical organ.²

For the general relationship between photon energy and collimator design, see our companion guide on gamma camera collimator selection.

Key Technical Principles

Collimator selection: why medium-energy

A parallel-hole collimator trades resolution against sensitivity through its septal thickness and hole geometry, and its septa must be thick enough to absorb the photons being imaged. A low-energy collimator is designed around ~140 keV; its thin septa are transparent to Ga-67's 300 and 393 keV photons, which pass through the lead between holes and are recorded at the wrong location — septal penetration, seen as star artifacts and a hazy loss of contrast.

The correct choice for gallium is a medium-energy (ME) collimator, whose thicker septa are sized to stop photons up to roughly 300–400 keV. A Monte Carlo evaluation of collimator and energy-window combinations for Ga-67 found the medium-energy collimator gave the best resolution-versus-sensitivity trade-off, with a primary-photon fraction near 83% compared with only about 34% for a low-energy high-resolution collimator — a direct measure of how much a low-energy collimator is corrupted by penetration.⁶

Energy windows and the count-sensitivity trade

Each photopeak is imaged with a percentage window — a band centered on the peak energy whose width is a fixed percentage of that energy. The window width in keV follows directly:

For a 20% window on the 184.6 keV peak:

A wider window captures more primary counts but also admits more scatter, degrading contrast; a narrower window is cleaner but count-starved. The triple-window design is itself a sensitivity strategy: because Ga-67's signal is split across several low-yield lines, acquiring three peaks simultaneously roughly triples the usable primary counts relative to imaging the 93 keV peak alone.⁶

Dosimetry

Gallium-67's slow clearance and multi-day residence give it a comparatively high patient dose for a diagnostic SPECT agent. Using the ICRP Publication 128 effective-dose coefficient, the effective dose scales linearly with administered activity:

For a typical adult administered activity of 185 MBq (5 mCi):

That is several times the effective dose of a typical Tc-99m bone scan and comparable to or greater than an FDG PET/CT study, which is one reason gallium is no longer a first-line choice where alternatives exist.⁷⁸ The critical organ — the tissue receiving the highest absorbed dose — is the lower large intestine (colon), because gallium is excreted slowly through the bowel; bowel preparation is often used both to reduce colonic dose and to clear the normal-variant colonic activity that can be mistaken for pathology.¹

Because the physical half-life is 3.26 days, decay correction over an imaging protocol is non-trivial. Activity remaining at time t after calibration follows:

so a dose calibrated at 185 MBq and imaged 72 hours (3.0 days) later has decayed to roughly 98 MBq — a reminder that gallium's long half-life makes both scheduling and radioactive-waste decay-in-storage planning materially different from short-lived agents.

Clinical Impact

Gallium's clinical value has always been its biology: it accumulates in a range of inflammatory, infectious, and neoplastic processes without requiring cell labeling. That breadth made it a general-purpose "something is wrong somewhere" agent for fever of unknown origin and occult infection, and a staple of lymphoma imaging before FDG.²³

The modern picture is one of a narrowed but real niche. In direct comparison for malignant lymphoma, FDG PET substantially outperformed gallium scintigraphy in sensitivity, and PET's same-day, higher-resolution imaging is simply more practical.³ For musculoskeletal and spine infection, however, gallium — especially as SPECT/CT — retains defined utility: it has been a durable tool for spondylodiscitis, where combined bone and gallium imaging or gallium SPECT/CT can characterize spinal infection when FDG PET is unavailable.²⁴ Gallium SPECT/CT has also shown value in fever of unknown origin and in complex patients such as renal-impairment or transplant populations, where hybrid imaging localizes and characterizes findings that planar imaging leaves ambiguous.⁵⁹

The trade-offs are intrinsic, not fixable by technique: the 2-to-3-day delay to imaging, the relatively high patient dose, image quality below that of PET, and — increasingly — constrained supply of the radiopharmaceutical itself.⁴ A department choosing gallium today is generally doing so because FDG is unavailable, contraindicated, or non-diagnostic for the specific question.

Practical Optimization Tips

Get the acquisition physics right before the patient arrives

• Confirm the medium-energy collimator is installed. A low-energy collimator on a gallium study is a classic, image-ruining error — septal penetration will masquerade as diffuse uptake. Verify the collimator physically, not just in the protocol.
• Peak all three photopeaks. Set and verify 20% windows on the 93, 185, and 300 keV peaks. A photopeak that has drifted off-center loses counts and shifts scatter into the window.
• Match imaging time to counts, not habit. Because gallium is count-poor, planar and SPECT acquisition times must be long enough for statistically adequate images; copying a Tc-99m acquisition time will produce noisy gallium images.
• Use SPECT/CT when localization matters. For infection and especially spine imaging, the CT component resolves the anatomic ambiguity that limits planar gallium.⁴⁵

Manage the schedule, the bowel, and the waste

• Image at 48–72 hours. Earlier imaging shows blood-pool and soft-tissue background that has not yet cleared; the delay is what creates the contrast.⁴
• Consider bowel preparation. Colonic activity is both the dosimetric bottleneck and a common false-positive; laxatives are frequently used to clear it.
• Plan for decay-in-storage. With a 3.26-day half-life, gallium waste needs a longer decay-in-storage window than most Tc-99m or F-18 waste — build that into the hot-lab plan.

Quality control for a multi-photopeak agent

Gallium imaging rides on the standard gamma camera QC program — daily energy peaking and uniformity, periodic spatial resolution, sensitivity, and SPECT performance — but the multi-window setup adds specific checks: confirm uniformity and count rate across the actual triple-window acquisition, not just the daily Tc-99m flood, and verify that the summed-window image is free of penetration artifacts. For the broader SPECT program, see our guide to SPECT/CT quality control and, for the peaking foundation, gamma camera energy resolution QC.

Regulatory Considerations

Gallium-67 is byproduct material, so its medical use is governed by NRC or Agreement State radioactive-material licensing, and its imaging quality is governed by accreditation and professional practice standards. The two regimes operate together: the license controls possession, use, and radiation safety, while accreditation controls image quality and QC.

Key frameworks to reference:

• 10 CFR Part 35 (Medical Use of Byproduct Material) or the equivalent Agreement State program — governs authorized use of Ga-67 citrate, the authorized user and authorized medical physicist roles, and radiation safety procedures for handling, administration, and waste.
• 10 CFR Part 20 (Standards for Protection Against Radiation) — sets occupational and public dose limits and the survey, monitoring, and waste-handling framework that a gallium program must satisfy, including decay-in-storage of the longer-lived waste.
• FDA-approved labeling — gallium citrate Ga-67 injection is an approved radiopharmaceutical with defined indications and an adult administered-activity range on the order of 74–185 MBq (2–5 mCi); the package insert is the primary source for approved use and handling.¹
• SNMMI procedure standards and ICRP dosimetry — the SNMMI procedure standard for gallium scintigraphy in inflammation and ICRP Publication 128 dose coefficients provide the professional-practice and dosimetry basis for protocol design.⁷¹⁰

Among the states DRPS serves, Florida, Maryland, Virginia, California, Nevada, Pennsylvania, New York, and New Jersey are NRC Agreement States that license medical use of gallium under their own radiation-control rules, while Washington, DC and Delaware are regulated directly by the NRC. A facility must confirm which authority issues its license before relying on any specific procedural requirement.

Frequently Asked Questions (FAQs)

What is gallium-67 citrate used for?

Gallium-67 citrate is a nuclear medicine imaging agent historically used for staging lymphoma and Hodgkin's disease and for localizing infection and inflammation, including fever of unknown origin, sarcoidosis, and spondylodiscitis. Most of these indications have shifted to FDG PET/CT, but Ga-67 SPECT/CT retains a role where FDG is unavailable, particularly in spine infection.

Why does Ga-67 require a medium-energy collimator?

Ga-67 emits photons at 93, 185, 300, and 393 keV. A low-energy collimator's thin septa are penetrated by the higher-energy 300 and 393 keV photons, producing septal-penetration artifacts and star patterns. A medium-energy collimator has thicker septa sized to stop these photons, giving the best resolution-versus-sensitivity trade-off for gallium imaging.

What energy windows are used for gallium-67 imaging?

Gallium imaging typically uses a triple energy window centered on the 93, 185, and 300 keV photopeaks, most commonly with a 20% window on each peak. The 393 keV line is usually excluded because it contributes little to image quality and increases septal penetration. Using all three main peaks improves count sensitivity over single-window acquisition.

When are gallium-67 images acquired after injection?

Gallium images are usually acquired 48 to 72 hours after injection. Ga-67 clears slowly from blood pool and soft tissue, so the delay is needed to build adequate target-to-background contrast. This intrinsic 2-to-3-day delay, along with a relatively high patient dose, is one of the main disadvantages of gallium imaging compared with same-day FDG PET/CT.

What is the radiation dose from a gallium-67 study?

Using the ICRP Publication 128 effective-dose coefficient of about 0.1 mSv per MBq, a typical adult administered activity of 185 MBq (5 mCi) gives an effective dose of roughly 18.5 mSv. The critical organ — the tissue receiving the highest absorbed dose — is the lower large intestine (colon), because of slow bowel transit of gallium.

How is gallium-67 imaging quality controlled?

Ga-67 imaging relies on the standard gamma camera QC program — daily energy peaking and uniformity, plus periodic spatial resolution, sensitivity, and SPECT performance testing — but with attention to the multi-photopeak setup: correct medium-energy collimator, all three photopeaks peaked, and window widths verified. Multi-window uniformity and count rate should be confirmed before clinical acquisition.

Has FDG PET/CT replaced gallium-67 imaging?

For most lymphoma and infection/inflammation indications, yes — FDG PET/CT offers higher sensitivity, same-day imaging, and better spatial resolution. Gallium-67 has become a niche agent, used chiefly when FDG is unavailable or contraindicated, with spondylodiscitis being its most durable remaining application. It remains an excellent teaching case for multi-photopeak SPECT physics.

Key Takeaways

• Ga-67 is a four-photopeak, electron-capture emitter with a 3.26-day half-life, decaying to stable zinc-67; its 93, 185, 300, and 393 keV lines drive every acquisition decision.¹
• A medium-energy collimator is mandatory. The 300 and 393 keV photons penetrate low-energy septa; a Monte Carlo study measured a primary-photon fraction near 83% for a medium-energy collimator versus about 34% for a low-energy high-resolution one.⁶
• Acquire a triple energy window on the 93, 185, and 300 keV peaks, typically at 20% width, to recover count sensitivity from a low-yield, multi-line emitter.⁶
• Dose is relatively high. At about 0.1 mSv/MBq, a 185 MBq study delivers roughly 18.5 mSv, with the colon as the critical organ.⁷
• Image at 48–72 hours to let blood-pool and soft-tissue background clear.⁴
• FDG PET/CT has taken most indications; gallium's durable niche is spondylodiscitis and settings where FDG is unavailable, and it remains a superb teaching case for multi-photopeak SPECT physics.³⁴

Conclusion

Gallium-67 is a study in how photon physics dictates protocol. Four photopeaks force a medium-energy collimator and a triple-window acquisition; a low per-decay yield forces long imaging times; a slow biodistribution forces a multi-day delay and makes the colon the critical organ; a 3.26-day half-life reshapes both scheduling and waste handling. None of those choices is arbitrary — each traces directly to the decay scheme. FDG PET/CT has taken most of gallium's clinical territory, but the physics that gallium demands is the same physics behind every multi-energy gamma camera study, which is why understanding a gallium acquisition sharpens the whole nuclear medicine QC program. Where a facility still runs gallium, doing it well means getting the collimator, the windows, the timing, and the dose right — and being able to document each one.

How DRPS Can Help

Diagnostic Radiation Physics Services supports nuclear medicine facilities across the full imaging chain, from gamma camera and SPECT/CT acceptance and NEMA performance testing to protocol design, dosimetry review, and radiation safety. For multi-photopeak agents like gallium-67, that includes verifying collimator and energy-window setup, confirming multi-window uniformity, reviewing administered-activity and dosimetry practice, and preparing the program for accreditation — all performed by board-certified medical physicists. We provide PET/CT and nuclear medicine physics, accreditation support, and broader medical physics consulting.

DRPS supports facilities across our service locations, including Florida, Maryland, Virginia, Washington DC, California, Nevada, New York, Pennsylvania, New Jersey, and Delaware.

Getting a gallium study right is a small test of a bigger principle: a nuclear medicine program that understands its photons will image every agent better.

Related Resources

• Gamma camera collimator selection
• SPECT/CT quality control
• Gamma camera energy resolution QC
• White blood cell infection imaging with In-111 HMPAO
• Brain FDG PET in dementia and epilepsy
• PET/CT and nuclear medicine physics
• Medical physicist consulting

References

1. U.S. Food and Drug Administration; Curium US LLC. Gallium Citrate Ga 67 Injection — Prescribing Information (ANDA 017478). 2018. accessdata.fda.gov
2. Palestro CJ. Radionuclide imaging of musculoskeletal infection: a review. J Nucl Med. 2016;57(9):1406-1412. doi:10.2967/jnumed.115.157297. PubMed
3. Shen YY, Kao A, Yen RF. Comparison of 18F-FDG PET and gallium-67 citrate scintigraphy for detecting malignant lymphoma. Oncol Rep. 2002;9(2):321-325. PubMed
4. Raghavan M, Palestro CJ. Imaging of spondylodiscitis: an update. Semin Nucl Med. 2023;53(2):152-166. doi:10.1053/j.semnuclmed.2022.11.005. PubMed
5. Serrano Vicente J, Parras Castañera E, Infante Torre JR, et al. 67-Gallium SPECT/CT in febrile syndromes of unknown origin. Rev Esp Med Nucl Imagen Mol. 2018;37(6):354-358. doi:10.1016/j.remn.2018.05.003. PubMed
6. Ouahman M, Errifai R, Asmi H, et al. Collimator and energy window evaluation in Ga-67 imaging by Monte Carlo simulation. Mol Imaging Radionucl Ther. 2020;29(3):118-123. doi:10.4274/mirt.galenos.2020.21549. PubMed
7. Andersson M, Johansson L, Minarik D, Leide-Svegborn S, Mattsson S. Effective dose to adult patients from 338 radiopharmaceuticals estimated using ICRP biokinetic data, ICRP/ICRU reference phantoms and ICRP 2007 tissue weighting factors. EJNMMI Phys. 2014;1(1):9. doi:10.1186/2197-7364-1-9. PubMed
8. Raghavan M, Lazzeri E, Palestro CJ. Imaging of spondylodiscitis. Semin Nucl Med. 2018;48(2):131-147. doi:10.1053/j.semnuclmed.2017.11.001. PubMed
9. Nowosinska E, Navalkissoor S, Quigley AM, Buscombe JR. Is there a role for gallium-67 citrate SPECT/CT in patients with renal impairment or renal transplant recipients in identifying suspected infection? World J Nucl Med. 2015;14(3):184-188. doi:10.4103/1450-1147.163250. PubMed
10. International Commission on Radiological Protection. ICRP Publication 128: Radiation Dose to Patients from Radiopharmaceuticals — A Compendium of Current Information Related to Frequently Used Substances. Ann ICRP. 2015;44(2 Suppl). icrp.org
11. Society of Nuclear Medicine and Molecular Imaging. Procedure Standard for Gallium Scintigraphy in Inflammation. SNMMI. snmmi.org
12. National Nuclear Data Center, Brookhaven National Laboratory. NuDat / ENSDF evaluated nuclear decay data for Ga-67. nndc.bnl.gov